How many people in the UK are on weight loss injections right now?

How the UK's injection-using population grew so quickly

It's a question our prescribers hear most weeks: am I unusual for wanting this, or is everyone on it? The honest answer is that the treatment population has grown faster than most health policy analysts predicted. When NICE approved semaglutide (Wegovy) in 2023 for specialist weight management services, the NHS waiting lists were already long. Private clinics and online pharmacies with GPhC-registered prescribers stepped in to meet demand that the NHS couldn't absorb immediately, and uptake through the private route accelerated sharply.

By early 2024, NHS England data indicated that semaglutide prescriptions for weight management had reached into the hundreds of thousands annually, and tirzepatide was added to the mix when NICE recommended it in December 2024. From June 2025, eligible patients began receiving tirzepatide through GP practices under a new NHS commissioning arrangement (not just specialist services) which pushed numbers higher still. Scotland, Wales and Northern Ireland have run parallel but distinct access criteria, so the UK total draws from several commissioning streams at once. For a fuller picture of the different injection options available, it helps to understand which medicines are counted in these figures and which are not.

Private prescribing, by its nature, isn't captured in NHS datasets the same way. Independent estimates from market analysts suggest the combined NHS and private pool of people currently using a GLP-1 weight loss injection in the UK runs into the low hundreds of thousands at any given point, with the trajectory still upward as NHS rollout phases widen eligibility.

Who these injections are actually licensed for

The numbers only make sense once you understand the eligibility picture. Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. That definition covers a substantial portion of the adult UK population, around two-thirds of adults in England are living with overweight or obesity, according to the Health Survey for England.

NICE eligibility for NHS tirzepatide (TA1026) is stricter: currently a BMI of 40 or above with four or more qualifying conditions, widening in stages through to 2027. Lower thresholds apply for adults from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance. Wegovy on the NHS is routed through specialist weight management services under TA875. The private route through a regulated pharmacy follows the licensed criteria (a BMI of 30 or above, or 27 with a relevant condition) without a referral or waiting list, subject to a clinician confirming you're suitable. Because these injections are licensed for people without diabetes too, the eligible population is much wider than many people initially assume.

BMI alone is never the whole picture. A prescriber looks at your medical history, current medicines, and any conditions that might affect safety, which is exactly why the prescription-only status exists.

Why global demand shapes what's available here

The UK sits inside a global surge. Eli Lilly and Novo Nordisk have both publicly cited unprecedented demand as the reason for supply constraints at various points since 2023. In the US, tirzepatide had over two million active prescriptions within its first year as a weight management medicine. In the UK, the same molecule was dispensed through both NHS pilot programmes and private pharmacies as quickly as licensed supply allowed.

That international demand has practical consequences: it's one reason the private cost of these medicines rose, Eli Lilly adjusted the UK list price for Mounjaro in September 2025, with reported private prices now ranging roughly £149 to £375 per month depending on dose and provider. If the cost side of the picture matters to you, the full breakdown of what drives those prices is worth reading before you compare providers. Understanding the real evidence behind weight loss injections also helps set realistic expectations about results, trial data shows meaningful average weight loss, but individual outcomes vary and depend heavily on sustained clinical support.

Global demand also gave rise to a counterfeit market. The MHRA seized approximately 20 million doses of illegally traded weight loss medicines worth around £45m in 2025 alone, including the first UK raid on a site manufacturing fake tirzepatide pens. Anyone buying through an unverified seller takes a serious risk. A GPhC-registered pharmacy, verifiable on the GPhC register, is the only safe source for a genuine, licensed supply.

What this means if you're deciding whether to start

The size of the treatment population tells you the evidence base is substantial and that these medicines are genuinely mainstream. It doesn't tell you whether they're right for you. Clinical trials in the SURMOUNT and STEP programmes involved thousands of adults with obesity, producing the average weight loss figures cited in NICE guidance, but averages sit inside a range, and the people at both ends of that range made the same decision to start. How your body responds, which dose you reach, and whether side effects are manageable are all things that emerge through treatment, not before it.

How many doses people end up taking is often another question that comes up early: how many injections are needed over a course of treatment depends on how your body responds and the clinical goals you set with your prescriber. If you are weighing up which medicine might suit you, reading about tirzee injection for weight loss can help clarify how the tirzepatide options compare before you speak to a prescriber. The injection technique itself is straightforward once shown, and guidance on administering a weight loss injection safely covers the practical steps in detail.

The decision worth focusing on isn't whether millions of other people are doing it. It's whether the clinical picture supports it for you specifically. That's a conversation for a prescriber, and at nume every consultation is reviewed by a GPhC-registered Independent Prescriber on the same day you submit it, a real clinician reading your answers, not automated software. If you'd like that review, speaking to our prescribers starts with a free consultation and no obligation to proceed.